logo-loader
viewOncoSenX

OncoSenX targeting solid tumors with its unique technology

OncoSenX Inc CEO Matthew Scholz sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The late stage pre-clinical cancer company, based in Seattle, Washington, targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

1 day, 19 hours ago

2 min read